Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using Toll-like receptor 7 agonist imiquimod as vaccine adjuvant

T cell-mediated immunity to microbes and to cancer can be enhanced by the activation of dendritic cells (DCs) via Toll-like receptors (TLRs). In this study, we evaluated the safety and feasibility of topical imiquimod, a TLR7 agonist, in a series of vaccinations (26) proteins,(27) and DNA, (28, 29)...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Adams, Sylvia, O'Neill, David W., Nonaka, Daisuke, Hardin, Elizabeth, Chiriboga, Luis, Siu, Kimberly, Cruz, Crystal M., Angiulli, Angelica, Angiulli, Francesca, Ritter, Erika, Holman, Rose Marie, Shapiro, Richard L., Berman, Russell S., Berner, Natalie, Shao, Yongzhao, Manches, Olivier, Pan, Linda, Venhaus, Ralph R., Hoffman, Eric W., Jungbluth, Achim, Gnjatic, Sacha, Old, Lloyd, Pavlick, Anna C., Bhardwaj, Nina
פורמט: Artigo
שפה:Inglês
יצא לאור: 2008
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2583094/
https://ncbi.nlm.nih.gov/pubmed/18566444
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים